Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]
Lupus landscape ‘poised for evolution’ as US doctors eagerly await new entrants
Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New biologics such as GSK’s Benlysta and AstraZeneca’s Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However, the landscape may be about to change with the […]
US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Despite favorable views on litifilimab, AbbVie’s Rinvoqand BMS’ Sotyktu capture the most prescriber interest for approval, accordingto Spherix Global Insights. EXTON, PA., September 12, 2024 — The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this debilitating and chronic disease. While Biogen’s litifilimab has […]
Rheumatologists’ Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s Saphnelo (anifrolumab) for SLE, […]
‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights. The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, […]
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious of all interleukins available in PsA. EXTON, PA., April 16, 2024 – In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA), ankylosing […]
Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira (adalimumab, AbbVie). This yawning gap underscores […]
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks to the surprising resilience of AbbVie’s autoimmune blockbuster. Now, in the face of lackluster Cytelzo sales, Boehringer has decided to prune its ranks in the U.S. and adopt […]
Charting New Paths: Non-TNF’s Evolving in Rheumatoid Arthritis Market
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market share, according to Spherix Global Insights. EXTON, PA., February 23, 2024 — Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer […]
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class, first established by Novartis’ Cosentyx and Eli Lilly’s Taltz, according to Spherix Global Insights. EXTON, PA., January 22, 2024 — Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment […]
